Global study marks major treatment advance for tough-to-treat high-risk blood cancer

Results from a new clinical trial led by Wake Forest University School of Medicine and Atrium Health Levine Cancer show that a new therapy could provide significantly better outcomes for patients with high-risk essential thrombocythaemia (ET), a type of blood cancer. The findings were recently published in The Lancet Haematology.